EGFR and neoplasm: A low-affinity anti-EGFR mAb (KD: 3.4 × 10−7 M) was efficiently taken up by cancer cells but not normal cells, which resulted in sufficient efficacy against tumor cells, but low toxicity against normal keratinocytes [33].